Skip to main content

Table 2 Patient characteristics and clinical outcomes

From: How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial

Variable Population (N = 9)
Age (years)
 Mean (Sd.) 70.8 (9.8)
 Median 71.0
 Min - Max 55.0–85.0
Gender (n)
 Male 7
 Female 2
Country (n)
 Germany 1
 USA 8
Overall response by IERC per RECIST at Week 13 / Week 25 (n)
 Partial / Complete responder 8 / 8
 Stable responder 0 / 0
 Progressive disease 1 / 1
  1. Sd standard deviation, USA United States of America, IERC Independent Endpoint Review Committee, RECIST Response Evaluation Criteria In Solid Tumors version 1.1